氟吡啶F-18 PET心肌灌注显像诊断疑似冠心病的研究设计与原理
本文描述了第二项FDA要求的F-18 Flurpiridaz PET心肌灌注显像前瞻性、开放标签、国际多中心3期试验的方法学。主要终点是评估该显像检测疑似冠心病患者显著CAD(定量有创冠状动脉造影≥50%)的诊断效能,次要终点是与Tc-99m SPECT MPI比较,并在女性、BMI≥30 kg/m2和糖尿病患者亚组中评估。
要点
- 主要终点:F-18 Flurpiridaz PET MPI检测疑似CAD患者显著CAD(ICA≥50%)的诊断效能。
- 次要终点:与Tc-99m SPECT MPI比较,全体及女性、BMI≥30、糖尿病亚组。
- 与第一项3期试验不同:SPECT比较为次要终点、排除已知CAD、SPECT和PET均在ICA前完成。
核心结论
- 第二项3期研究将为F-18 Flurpiridaz PET MPI检测显著CAD的诊断效能提供额外证据。
研究设计与样本
- 前瞻性、开放标签、国际多中心3期试验,试验注册号NCT03354273。
- 研究对象为疑似冠心病患者,排除已知CAD患者。
关键数值与推荐
- 主要终点:以定量有创冠状动脉造影≥50%为显著CAD标准,评估F-18 Flurpiridaz PET MPI的诊断效能。
- 次要终点:与Tc-99m标记SPECT MPI比较,在全体患者及女性、BMI≥30 kg/m2、糖尿病患者亚组中评估诊断效能。
临床怎么用
- 该试验设计支持在疑似CAD患者中评估F-18 Flurpiridaz PET MPI作为诊断工具,并与SPECT进行头对头比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Positron emission tomography (PET) myocardial perfusion imaging (MPI) with the novel radiopharmaceutical Fluorine-18 Flurpiridaz has been shown in Phase 1, 2, and first Phase 3 clinical studies to be safe and effective in diagnosing coronary artery disease (CAD). We describe the methodology of the second FDA-mandated phase 3 prospective, open-label, international, multi-center trial of F-18 Flurpiridaz PET MPI. METHODS: The primary study end point is to assess the diagnostic efficacy of F-18 Flurpiridaz PET MPI in the detection of significant CAD [≥ 50% by quantitative invasive coronary angiography (ICA)] in patients with suspected CAD. The secondary endpoints are to evaluate the diagnostic efficacy of F-18 Flurpiridaz PET MPI compared to Tc-99 m-labeled SPECT MPI in the detection of CAD in all patients and in the following subgroups: (1) females; (2) patients with body mass index ≥ 30 kg/m2; and (3) diabetic patients. This trial's design differs from the first phase 3 trial in that (1) comparison to SPECT is now a secondary end point; (2) patients with known CAD are excluded; and (3) both SPECT and PET MPI are performed before ICA. CONCLUSIONS: This second phase 3 study will provide additional evidence on the diagnostic efficacy of F-18 Flurpiridaz PET MPI in the detection of significant CAD. TRIAL REGISTRATION NUMBER: NCT03354273.
引用
- Bourque JM, Hanson CA, Agostini D, et al. Assessing myocardial perfusion in suspected coronary artery disease: rationale and design of the second phase 3, open-label multi-center study of flurpiridaz (F-18) injection for positron emission tomography (PET) imaging. J Nucl Cardiol. 2021. PMID: 33521873. doi:10.1007/s12350-021-02527-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。